How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?

Table 1 Asia-Pacific Colorectal Screening scoring system (adapted from Wang et al[53])

Risk factor	Criterion	Point
Age (yr)	< 50	0
	50-69	1
	≥ 70	2
Gender	Female	0
	Male	1
Immediate family member with colorectal cancer	No	0
	Yes	1
Smoking status	No smoking history	0
	Current or former smoker	1

Table 2 Risk score for advanced neoplasia (adapted from Segnan et al[11])

Risk factor	Category	Point
Age (yr)	40-49	0
	50-54	1
	55-59	2
	60-66	3
	> 66	3
Sex	Female	0
	Male	2
Family history	None	0
	1 first-degree relative ≥ 60 years old	1
	1 first-degree relative < 60 years old	2
	2 first-degree relatives	2
Smoking, pack years	None	0
	< 10	0
	10-19	1
	≥ 20	1
Body mass index (kg/m2)	< 25	0
	25-29	0
	≥ 30	1 - Female
		0 - Male

Table 3 Comparison of non-advanced adenoma and colorectal neoplasia in the target and control groups

	Target group (n = 726)	Control group (n = 774)	OR, 95%CI (P value)1
Adenoma, n	346	270	1.2, 0.9-1.5
(%, 95%CI)	(48%, 44%-51%)	(35%, 32%-38%)	(0.18)
Advanced adenoma, n	131	66	1.8, 1.2-2.5
(%, 95%CI)	(18%, 15%-21%)	(9%, 7%-11%)	(< 0.01)
Cancer, n	11	11	0.7, 0.3-1.6
(%, 95%CI)	(2%, 1%-3%)	(1%, 1%-3%)	(0.35)

¹Adjusted comparison by logistic regression - including age, sex and previous FIT+ (fecal immunochemical test positivity).

Table 4 Prevalence of non-advanced adenoma and colorectal neoplasia within the target group

	Combination of DM2 and SCORE ≥ 10 (n = 157)	SCORE ≥ 10 (n = 413)	DM2 (n = 156)	P value1
Adenoma, n	69	211	66	0.33
(%, 95%CI)	(44%, 36%-52%)	(51%, 46%-56%)	(42%, 34%-50%)
Advanced adenoma, n	25	89	17	< 0.05
(%, 95%CI)	(16%, 11%-23%)	(22%, 18%-26%)	(11%, 6%-17%)
Cancer, n	3	5	3	0.56
(%, 95%CI)	(2%, 0%-5%)	(1%, 0%-3%)	(2%, 0%-6%)

¹P value was obtained using a likelihood ratio test. The comparison models were adjusted for age, sex and previous FIT+ (fecal immunochemical test positivity). DM2: Type 2 diabetes mellitus; SCORE: Systematic COronary Risk Evaluation.